{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-088072","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.126736+00:00","generated_at":"2026-06-12T03:44:53.334426+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Marker Therapeutics reports non-clinical proof-of-concept data for MT-401 OTS, expects first patient treatment H1 2024","bullets":["Non-clinical data: MT-401 OTS killed AML cells in vitro with 2/8 HLA match, significantly reducing THP-1 cell growth.","FDA cleared clinical protocol for MT-401 OTS in relapsed/refractory AML; inventory of 8 donor lines established.","Single donor could treat ~40 patients; product stable >1 year; first patient treatment expected H1 2024.","OTS strategy aims to reduce manufacturing cost and turnaround time to as little as 72 hours."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-088072","json":"https://secwatch.observer/filing/0001104659-23-088072.json","markdown":"https://secwatch.observer/filing/0001104659-23-088072.md","text":"https://secwatch.observer/filing/0001104659-23-088072.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923088072/0001104659-23-088072-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923088072/tm2320895d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:44:53.334426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}